Kynurenine inhibits chondrocyte proliferation and is increased in synovial fluid of patients with septic arthritis

Journal of Orthopaedic Research

Volumn 28, Issue 11, 2010, Pages 1490-1496

  Lögters, Tim T ^a   Laryea, Maurice D ^a   Jäger, Marcus ^a   Schädel Höpfner, Michael ^a   Windolf, Joachim ^a   Flohé, Sascha ^a   Altrichter, Jens ^a   Scholz, Martin ^a   Paunel Görgülü, Adnana N ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Cartilage; Chondrocytes; Infection; Inflammatory markers; Tryptophan

Indexed keywords

C REACTIVE PROTEIN; KYNURENINE; TRYPTOPHAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CARTILAGE CELL; CELL CULTURE; CELL PROLIFERATION; CHEMISTRY; FEMALE; HUMAN; INFECTIOUS ARTHRITIS; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SYNOVIAL FLUID;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, INFECTIOUS; C-REACTIVE PROTEIN; CELL PROLIFERATION; CELLS, CULTURED; CHONDROCYTES; FEMALE; HUMANS; KYNURENINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; ROC CURVE; SYNOVIAL FLUID; TRYPTOPHAN;

EID: 77958009251     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21158     Document Type: Article

References (29)

1. Goldenberg DL. 1998. Septic arthritis. Lancet 351(9097) 197-202.
2. Tarkowski A. 2006. Infection and musculoskeletal conditions: Infectious arthritis. Best Pract Res Clin Rheumatol 20:1029-1044.
3. Weston VC, Jones AC, Bradbury N, et al. 1999. Clinical features and outcome of septic arthritis in a single UK Health District 1982-1991. Ann Rheum Dis 58:214-219.
4. Kaandorp CJ, Krijnen P, Moens HJ, et al. 1997. The outcome of bacterial arthritis: A prospective community-based study. Arthritis Rheum 40:884-892.
5. Kaandorp CJ, Dinant HJ, van de Laar MA, et al. 1997. Incidence and sources of native and prosthetic joint infection: A community based prospective survey. Ann Rheum Dis 56:470-475.
6. Mathews CJ, Coakley G. 2008. Septic arthritis: Current diagnostic and therapeutic algorithm. Curr Opin Rheumatol 20:457-462.
7. Mathews CJ, Kingsley G, Field M, et al. 2007. Management of septic arthritis: A systematic review. Ann Rheum Dis 66:440-445.
8. Li SF, Cassidy C, Chang C, et al. 2007. Diagnostic utility of laboratory tests in septic arthritis. Emerg Med J 24:75-77.
9. Li SF, Henderson J, Dickman E, et al. 2004. Laboratory tests in adults with monoarticular arthritis: Can they rule out a septic joint? Acad Emerg Med 11:276-280.
10. Margaretten ME, Kohlwes J, Moore D, et al. 2007. Does this patient have septic arthritis? JAMA 297:1478-1488.
11. Swan A, Amer H, Dieppe P. 2002. The value of synovial fluid assays in the diagnosis of joint disease: A literature survey. Ann Rheum Dis 61:493-498.
12. McGillicuddy DC, Shah KH, Friedberg RP, et al. 2007. How sensitive is the synovial fluid white blood cell count in diagnosing septic arthritis? Am J Emerg Med 25:749-752.
13. Taylor MW, Feng GS. 1991. Relationship between interferongamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 5:2516-2522.
14. Baban B, Hansen AM, Chandler PR, et al. 2005. Aminor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol 17(7)909-919.
15. Kwidzinski E, Bechmann I. 2007. IDO expression in the brain: A double-edged sword. J Mol Med 85(12)1351-1359.
16. Bozza S, Fallarino F, Pitzurra L, et al. 2005. A crucial role for tryptophan catabolism at the host/Candida albicans interface. J Immunol 174:2910-2918.
17. Brown RR, Ozaki Y, Datta SP, et al. 1991. Implications of interferon-induced tryprophan catabolism in cancer, autoimmune diseases and AIDS. Adv Exp Med Biol 294:425-435.
18. Müller A, Heseler K, Schmidt SK, et al. 2008. The missing link between indoleamine 2, 3-dioxygenase mediated antibacterial and immunoregulatory effects. J Cell Mol Med [epub ahead of print].
19. Schmidt SK, Müller A, Heseler K, et al. 2009. Antimicrobial and immunoregulatory properties of human tryptophan 2, 3-dioxygenase. Eur J Immunol 39(10)2755-2764.
20. Mellor AL, Munn DH. 2004. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol 4:762-774.
21. Moffett JR, Namboodiri MA. 2003. Tryptophan and the immune response. Immunol Cell Biol 81:247-265.
22. Lögters TT, Laryea MD, Altrichter J, et al. 2009. Increased plasma kynurenine values and kynurenine: Tryptophan ratios after major trauma are early indicators for the development of sepsis. Shock 32(1)29-34.
23. Pellegrin K, Neurauter G, Wirleitner B, et al. 2005. Enhanced enzymatic degradation of tryptophan by indoleamine 2,3-dioxygenase contributes to the tryptophan-deficient state seen after major trauma. Shock 23(3)209-215.
24. Widner B, Werner ER, Schennach H, et al. 1997. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 43:2424-2426.
25. Lögters T, Paunel-Görgülü A, Zilkens C, et al. 2009. Diagnostic accuracy of neutrophil-derived circulating free DNA (cf-DNA/NETs) for septic arthritis. J Orthop Res 27(11)1401-1407.
26. Bertazzo A, Punzi L, Bertazzolo N, et al. 1999. Tryptophan catabolism in synovial fluid of various arthropathies and its relationship with inflammatory cytokines. Adv Exp Med Biol 467:565-570.
27. Schwarcz R, Whetsell WO, Jr., Mangano RM. 1983. Quinolinic acid: An endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219:316-318.
28. Parada-Turska J, Rzeski W, Zgrajka W, et al. 2006. Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid, inhibits proliferation of synoviocytes In vitro. Rheumatol Int 26:422-426.
29. Smith AJ, Stone TW, Smith RA. 2007. Neurotoxicity of tryptophan metabolites. Biochem Soc Trans 35:1287-1289.